We are studying whether Dapagliflozin can help slow the progression of kidney disease in adolescents and young adults with Alport syndrome. This trial aims to improve treatment options for those with this condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Alport's syndrome is a rare genetic disorder that affects the kidneys, leading to progressive kidney disease, as well as hearing loss and eye abnormalities. It is caused by mutations in genes responsible for collagen production, which is essential for the structure of various tissues in the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.